 The FDA's Office of Generic Drugs has developed scientific research programs to accelerate the development and assessment of generic drugs using model-integrated alternative B approaches. These include PBPK modeling for ophthalmic, injectable, nasal, and implant drug products. The purpose of this workshop was to provide research updates and information on the current state of the use of PBPK, modeling approaches to support generic product development. This article was authored by Mingliong Tan, Sajiv Chandran, Rebecca Jarab, and others.